Results 211 to 220 of about 162,481 (277)

GenIV vaccines: bridging innovation to equity in neglected tropical diseases. [PDF]

Front Immunol
Araújo M, Gurjar D, Grandchamp N, Saha B, Silvestre R.   +4 more
europepmc   +1 more source

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy

Advanced Science, EarlyView.
This study identifies Lactobacillus rhamnosus as an intrinsic oncolytic agent that triggers tumor metabolic collapse via calcium‐dependent ROS bursts. By chemically anchoring collagen‐targeting “molecular pili” to the bacterial surface, the engineered non‐transgenic probiotic (LR@MP) achieves targeted colonization and potent solid tumor suppression ...
Haodong Ge, Chengsheng Ding, Xiao Yang, Si Gao, Changjie Yang, Yuchen Hou, Hongye Wang, Linke Bian, Hao Zhong, Yifan Qu, Luyang Zhang, Junjun Ma, Zhengwei Cai, Wenguo Cui, Minhua Zheng   +14 more
wiley   +1 more source

Editorial: The future of agricultural biosafety regulations. [PDF]

Front Bioeng Biotechnol
Garcia-Alonso M, Rubinstein C, Smyth SJ, Vicien C.   +3 more
europepmc   +1 more source

Molecular Biosafety [PDF]

Applied Biosafety, 2007
openaire   +3 more sources

Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility

Advanced Science, EarlyView.
We identify an antagonistic ubiquitin circuit that controls cellular permissiveness to multiple coronaviruses. The deubiquitinase USP7 stabilizes the epigenetic regulator KDM6A to upregulate viral receptors, while the E3 ligase RNF40 degrades KDM6A by catalyzing K6/K11‐ubiquitin chains of KDM6A for autophagic degradation.
Meng‐Zhuo Huang, Zhong‐Yuan Yang, Shi Wang, Yan Ge, Lan Lin, Mia Madel Alfajaro, Renata B. Filler, Wan‐Yao Song, Ming‐Zhu Kong, Jin Wei   +9 more
wiley   +1 more source

Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus. [PDF]

Signal Transduct Target Ther
Zhang Y, Tang S, Chen L, Song S, Cao J, Tian G, Xiao G, Shen J, Zhang L.   +8 more
europepmc   +1 more source

Engineered Bacteria Factory Integrating Drug Delivery and Antibody Manufacture for Activating the STING Signal Pathway Mediated Tumor Immunotherapy

Advanced Science, EarlyView.
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong, Tian Yao, Yong Li, Zi‐Hui Yan, Xiao‐Ting Xie, Jia‐Hua Zou, Kai Cheng, Jin‐Xuan Fan, Yuan‐Di Zhao, Qiu‐Ran Xu   +9 more
wiley   +1 more source

Being a woman researcher in dangerous laboratories: biosafety level 3 and tuberculosis. [PDF]

Philos Ethics Humanit Med
Yıldırım K, Koçak O, Baran M, Ataş C, Akçit ET, Licina M, Bozkurt N, Çoban M, Gün MA, Özler S, Oktan T, Şimşek E, Çoban AY.   +12 more
europepmc   +1 more source

Targeted H2S Delivery System Attenuates Blood‐Spinal Cord Barrier Disruption after Spinal Cord Injury by Reshaping the Ferritinophagy Pathway

Advanced Science, EarlyView.
The αvβ3‐mediated SPRC@MPDA‐RGD targets broken endothelial cells and controllably releases SPRC. CSE is then activated to produce endogenous H2S, which inhibits ferritinophagy. In brief, H2S inhibits autophagy by activating the PI3K/Akt/mTOR pathway, thereby suppressing the ferroptosis process mediated by NCOA4, and ultimately promoting the ...
Zhiheng Chen, Xinkai Pu, Ruiyang Li, Yuezhou Wu, Qirong Zhou, Jian Wang, Yuxuan Qian, Fengjie Lu, Jian‐Yuan Zhao, Zhida Su, Jiacan Su, Xiaofeng Lian   +11 more
wiley   +1 more source

Author Correction: CAPRIN1specifically mediates m⁶A modification of RIG-I RNA to inhibit Mycobacterium Tuberculosis infection. [PDF]

Commun Biol
Zhou L, Chen H, Jiang D, Xu X, Li Z, Zheng R, Huang J, Ling Y, Liao Y, Wang H, Pan P, Jiang J, Ye L, Lee WS, Chen Y, Lee SY, Lv X, Chu J, Liang H, An S.   +19 more
europepmc   +1 more source